Axim Biotechnologies, Inc. · OTC:AXIM
Axim Biotechnologies — Investor Presentation (July 2021)
25 slides from Axim Biotechnologies's investor presentation, July 2021
Slide 1: Company Presentation
OTC MARKETS: SYMBOL: AXIM Company Presentation July 2021
Slide 2: Safe Harbor
SAFE HARBOR The statements made by Axim Biotechnologies Inc., in this presentation may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-
Slide 3: About
ABOUT • AXIM is focused on changing outcomes for Cancer and Covid-19. • Developing rapid diagnostic tests for the early detection of cancer and therapeutics to suppress metastasis, licensed from Mayo Clinic and Arizona State University. • National Cancer Institute awarded $400,000 SBIR phase I Grant
Slide 4: World Class Science Team
WORLD CLASS SCIENCE TEAM John Huemoeller II Sergei Svarovsky, PhD, MBA Douglas Lake, PhD 35 years in financial markets. Investment Physical Chemist, with NCI, Pfizer Associate Professor, ASU and Mayo Clinic. Banker, Drexel, Smith Barney, Paine Weber. Point-of-Care diagnostic projects Philips, Roche,
Slide 5: QSOX1 Shown to Be Highly Specific for Malignant Cancers
QSOX1-- SHOWN TO BE HIGHLY SPECIFIC FOR MALIGNANT CANCERS QSOX1 • We discovered Quiescin Sulfhydryl Oxidase 1 (QSOX1) as a Biomarker in tumor derived proteins. • QSOX1 is over-expressed in multiple human cancers, it is not expressed or minimally expressed in non-malignant tissues. • We believe QSOX1
Slide 6: QSOX1 Is a Master Regulator of Disulfide Bond Formation
QSOX1 IS A “MASTER REGULATOR” OF DISULFIDE BOND (DSB) FORMATION The extracellular matrix (ECM) is a collection of proteins secreted by tumor cells and tumor associated fibroblasts. Its forms a barrier in and around tumors. All ECM proteins have disulfide bonds. Targeting the enzyme (QSOX1) that make
Slide 7: World's First Rapid Diagnostic Test for QSOX1-L Using Drop of Blood
WORLD’S FIRST RAPID DIAGNOSTIC TEST FOR QSOX1-L USING DROP OF BLOOD Low cost, non-invasive Rapid Diagnostic Test for point-of-care for multiple cancers Apply drop of blood Read out result in 10 minutes 7
Slide 8: QSOX1-L Detection
QSOX1-L DETECTION QSOX1 Levels in Different Sample Pools 40.2 23.5 0.2 0.4 0.4 0.4 2.3 BLANK CONTROL SIGMA NORMAL MAYO NORMAL INNOVATIVE SAN DIEGO BLOOD MAYO CANCER POOL, MAYO CANCER POOL, POOL, N>1,000 POOL, N=4 RESEARCH NORMAL BANK NORMAL POOL, N=7 N=200 POOL, N>1,000 N=20
Slide 9: Detection of QSOX1 Peptide in Plasma from Melanoma and Lung Cancer Patients
QSOX1 PEPTIDE Detection IN PLASMA of QSOX1 FROM MELANOMA peptide in plasmaAND LUNG CANCER PATIENTS from Melanoma and Lung cancer patients * 1-2 cm nodule by radiographic imaging (biopsy-confirmed cancer) Ctrl n=5 Melanoma n=3 Lung cancer* n=3 9
Slide 10: Mayo Clinic Screened 50,000 Compounds to Find SBI-183
MAYO CLINIC SCREENED 50,000 COMPOUNDS TO FIND SBI-183 SBI-183 inhibits QSOX1L and therefore suppresses tumor growth in mice Mouse xenograft Renal Cell model: Carcinoma UOK117 Kidney 800 cancer Untreated 600 Tumor Volume (mm3) 400 Vehicle 200 ** * 0 Day 0 Day 4 Day 6 Day 9 Day 11 Day 13 Day 15 Day 17
Slide 11: Can We Make SBI-183 Better? SPX-009 Is 10X More Potent
NOW THE QUESTION? CAN WE MAKE SBI-183 BETTER? ANSWER IS YES SPX-009 is 10X more potent then SBI-183: Triple negative breast cancer Sarcomatoid kidney cancer Day 3 Day 3 .01% Veh Potency increased .01% Veh 10-fold over SBI-183 1250nM SPX-009 1250nM SPX-009
Slide 12: Licensing Compound from Mayo Clinic Saved Years of Development Time
SOURCE:FDA WE ARE HERE LICENSING COMPOUND FROM MAYO CLINIC SAVED US YEARS OF DEVELOPMENT TIME AND MONEY
Slide 13: Oncology Market Size
ONCOLOGY MARKET SIZE The global oncology drug market will reach $176 billion by 2025. The global cancer diagnostics market will grow to $249.6 billion over next 6 years.* • QSOXL is over expressed in 10 cancers including lung, prostate, breast, brain, kidney, bladder, pancreatic. • Gives AXIM a pipe
Slide 14: COVID-19
COVID-19 • Early in the pandemic we decided to utilize our cancer diagnostics expertise to develop rapid tests for COVID-19 • We have now developed 4 different tests to measure neutralizing antibodies (Nabs): LFA for plasma, ELISA, AlphaLisa and LFA for whole blood • 3 POC studies completed • Robust
Slide 15: Not All Antibodies Are Created Equal
NOT ALL ANTIBODIES ARE CREATED EQUAL • Only NAbs block binding and entry of the SARS-CoV-2 virus into human host cells. • However, despite recovering from the disease, not all individuals make high levels of Nabs. • Up to 30% do not make measurable levels of NAbs • The goal of all COVID-19 vaccines
Slide 16: Lateral Flow POC Test
LATERAL FLOW POC TEST • Drop of whole blood • Rapid: 10 minutes time to result • Portable • Inexpensive compared to laboratory tests • Point-of-Care/At Home Testing/Telemedicine • Monitors rise and fall in neutralizing Finger- antibodies in response to vaccine or natural infection Stick whole blood
Slide 17: ROC Comparison of Ortho Vitros to Axim ImmunoPass
ROC Comparison of Ortho Vitros SARS-CoV-2 Total Ig to Axim ImmunoPass Receiver Operating Characteristic (ROC) Analysis: Ortho vs SARS-CoV-2 microneutralization LFA vs SARS-CoV-2 microneutralization Accuracy Ortho 85.8% Axim 97.8%
Slide 18: Manufacturing - Partnership
LFA Manufacturing MANUFACTURING - PARTNERSHIP Empowered Diagnostics, Inc. Signed Distribution and Manufacturin • Pompano Beach, Florida, USA g Agreement • Facility was the largest lateral flow pregnancy test manufacturer in the World • Tech transfer complete • EUA filed for Point-Of-Care with FDA •
Slide 19: Signed Distribution and Manufacturing Agreement; ImmunoPass
Immunopass Signed Distribution and Manufacturin g Agreement
Slide 20: Axim Manufactures All the Biologics Internally
AXIM MANUFACTURES ALL THE BIOLOGICS INTERNALLY – BSL2 LAB IN SAN DIEGO • We foresaw the supply chain problem early-on • China - Expensive • We make all the biological ingredients – ACE2, spike proteins, control proteins, monoclonals, polystreptavidin • Our ACE2 is 10 times more potent and longer she
Slide 21: What We Are Doing Right Now
WHAT WE ARE DOING RIGHT NOW • Continue developing analogs to SBI-183 for QSOX1L suppression (>200) • BARDA added grant proposals (March 23) for Nabs tests • Beginning OTC study – including reader/phone app • Developing Generation 2 & 3 NAbs rapid diagnostic tests • Intellectual Property: two more pa
Slide 22: Relative Neutralization Activity Against Variants
Relative neutralization activity of donor’s plasma and serum samples recovered from COVID-19 and immunized with vaccine tested by competitive ELISA with RBD proteins from Wuhan (WU), Brazil (BZ), South-Africa (SA), California (CA), Britain (BT) and Bristol (BS) 120 WU BZ SA CA BT BS 100 80 % Neutral
Slide 23: Not All Vaccines Are Created Equal
NOT ALL VACCINES ARE CREATED EQUAL H MH M-MH M M-ND ND Vaccine NAbs study with >400 people at ASU & Mayo Clinic
Slide 24: Summary
SUMMARY • World Class Science Team • The ONLY test that matters in a post vaccine world is one that measures neutralizing antibodies. • We have the best – Period!!!!! - Accurate, Fast, Portable, Inexpensive • Manufacturing agreement - ramping up to 7 million tests a week • Expect Revenue in 2nd Qt -
Slide 25: For Further Information, Please Contact
For further information, please contact: John Huemoeller II – CEO Tel. +1 858-923-4422 [email protected] www.aximbiotech.com
Axim Biotechnologies — Investor Presentation (July 2021) on 6ix